Response to imatinib mesylate in a patient with idiopathic hypereosinophilic syndrome associated with cyclic eosinophil oscillations

International Journal of Hematology

Volumn 81, Issue 4, 2005, Pages 310-314

  Imashuku, Shinsaku ^a,b   Kakazu, Naoki ^c   Ueda, Ikuyo ^d   Morimoto, Akira ^d   Harada, Hironori ^e   Teramura, Tomoko ^a   Tamura, Shinichi ^b   Fukushima Nakase, Yoko ^b   Kuroda, Hiroshi ^b  

^a Takasago seibu Hospital   (Japan)

^b KYOTO CITY HOSPITAL   (Japan)

^c KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^d KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^e HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Chung Strauss syndrome; Idiopathic hypereosinophilic syndrome; Imatinib mesylate; Mast cell; Platelet derived growth factor receptor (PDGFR); Tryptase

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; CREATININE; FRUCTOSE BISPHOSPHATE ALDOLASE; IMATINIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LACTATE DEHYDROGENASE; M PROTEIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PREDNISOLONE; TRYPTASE; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; BURSITIS; CASE REPORT; DOSE RESPONSE; DRUG EFFECT; EDEMA; ENZYME BLOOD LEVEL; EOSINOPHIL; FLUORESCENCE IN SITU HYBRIDIZATION; FUSION GENE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HYPEREOSINOPHILIA; HYPEREOSINOPHILIC SYNDROME; IDIOPATHIC DISEASE; LABORATORY TEST; MALE; OSCILLATION; PROTEIN BLOOD LEVEL; GENETICS; NUCLEOTIDE SEQUENCE; RECURRENT DISEASE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC AGENTS; DNA MUTATIONAL ANALYSIS; HUMANS; HYPEREOSINOPHILIC SYNDROME; MALE; PIPERAZINES; PYRIMIDINES; RECEPTORS, PLATELET-DERIVED GROWTH FACTOR; RECURRENCE; TREATMENT OUTCOME;

EID: 22844438963     PISSN: 09255710     EISSN: None     Source Type: Journal    
DOI: 10.1532/IJH97.04185     Document Type: Article

References (22)

1. Gleich GJ, Leiferman KM, Pardanani A, Tefferi A, Butterfield JH. Treatment of hypereosinophilic syndrome with imatinib mesilate. Lancet. 2002;359:1577-1578.
2. Cools J, DeAngelo DJ, Gotlib J, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med. 2003;348:1201-1214.
3. Pardanani A, Reeder T, Porrata LF, et al. Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders. Blood. 2003;101:3391-3397.
4. Cortes J, Ault P, Koller C, et al. Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome. Blood. 2003; 101:4714-4716.
5. Klion AD, Noel P, Akin C, et al. Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness. Blood. 2003;101:4660-4666.
6. Wilkinson K, Velloso ER, Lopes LF, et al. Cloning of the t(1;5) (q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib. Blood. 2003;102:4187-4190.
7. Pardanani A, Ketterling RP, Brockman SR, et al. CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy. Blood. 2003;102:3093-3096.
8. Noth I, Strek ME, Leff AR. Churg-Strauss syndrome. Lancet. 2003; 361:587-594.
9. Moor JW, U-King Im J, MacDonald AW, Whitehead E. Limited form of Churg-Strauss syndrome presenting as a mass in the neck. J Laryngol Otol. 2002;116:966-968.
10. Leon-Ruiz L, Jimenez-Alonso J, Hidalgo-Tenorio C, et al. Churg-Strauss syndrome complicated by endomyocardial fibrosis and intraventricular thrombus: importance of the echocardiography for the diagnosis of asymptomatic phases of potentially severe cardiac complications. Lupus. 2002;11:765-767.
11. Val-Bernal JF, Mayorga M, Garcia-Alberdi E, Pozueta JA. Churg-Strauss syndrome and sudden cardiac death. Cardiovasc Pathol. 2003;12:94-97.
12. Hirota S, Ohashi A, Nishida T, et al. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology. 2003;125:660-667.
13. Heinrich MC, Corless CL, Duensing A, et al. PDGFRA activating mutations in gastrointestinal stromal tumors. Science. 2003;299:708-710.
14. Bain BJ. Cytogenetic and molecular genetic aspects of eosinophilic leukaemias. Br J Haematol. 2003;122:173-179.
15. Frickhofen N, Marker-Hermann E, Reiter A, et al. Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib. Ann Hematol. 2004;83:477-480.
16. Pardanani A, Brockman SR, Patermoster SF, et al. FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia. Blood. 2004;104:3038-3045.
17. Wolf D, Gastl G, Rumpold H. Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib [in German]. Dtsch Med Wochenschr. 2004;129:2104-2106.
18. Musto P, Falcone A, Sanpaolo G, et al. Heterogeneity of response to imatinib-mesylate (Glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis. Leuk Lymphoma. 2004;45:1219-1222.
19. Tan D, Hwang W, Ng HJ, Goh YT, Tan P. Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report. Int J Hematol. 2004;80:75-77.
20. Xiao Z, Hao Y, Qin T, Han Z. Periodic oscillation of blood leukocytes, platelets, and hemoglobin in a patient with chronic eosinophilic leukemia. Leuk Res. 2003;27:89-91.
21. Malcovati L, La Starza R, Merante S, Pietra D, Mecucci C, Cazzola M. Hypereosinophilic syndrome and cyclic oscillations in blood cell counts: a clonal disorder of hematopoiesis originating in a pluripotent stem cell. Haematologica. 2004;89:497-499.
22. Pottier P, Planchon B, Grossi O. Complete remission with imatinib mesylate (Glivec) of an idiopathic hypereosinophilic syndrome associated with a cutaneous mastocytosis after failure of interferon-alpha [in French]. Rev Med Interne. 2003;24:542-546.